Visiox Pharmaceuticals Merges with Ocuvex Therapeutics
Columbus, Ohio-based Visiox Pharmaceuticals announced on August 20 that it entered into a definitive merger agreement with Ocuvex Therapeutics, Inc. Ocuvex Therapeutics is a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders. It boasts a pipeline of near-term ophthalmic medicines. Visiox Pharmaceuticals is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Visiox’ products, including OMLONTI® (omidenepag isopropyl ophthalmic solution), PDP-716... Read More »
Recursion and Exscientia Merge
On August 8, Recursion and Exscientia announced plans to merge. The combined company is estimated to achieve annual synergies of approximately $100 million with a runway extending into 2027. Exscientia is a global pharmatech company using patient-first artificial intelligence to discover better drugs. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. According to the company’s financial report, the company generated revenue of $25.6 million for the 12 months ending on December 31, 2023. Recursion is a clinical stage biotechnology company decoding biology to industrialize... Read More »
Earnings Week in Review: Healthcare Giants Navigate Growth and Hurdles
We’re taking a look at some of the major companies reporting earnings in the week of July 15-July 19, across a variety of sectors. UnitedHealth Group and Novartis showcased strong growth, while Johnson & Johnson and Elevance Health presented more mixed results. Abbott Laboratories also reported solid results, driven by its medical devices segment, while facing challenges in its diagnostics business due to waning COVID-19 testing demand. This week’s earnings reports offer insights into the broader healthcare industry’s performance and future trajectory. UnitedHealth Group UnitedHealth Group (UHG) demonstrated a significant turnaround in its second quarter of 2024, posting a... Read More »
ANI Pharmaceuticals Buys Alimera Sciences
Baudette, Minnesota-based drug manufacturer ANI Pharmaceuticals announced that it will acquire Alimera Sciences. ANI Pharmaceuticals will acquire Alimera with cash and financing, paying $5.50 per share — a 75% premium over Alimera’s previous close, plus as much as 50¢ per share more should the business hit revenue goals in 2026 and 2027. The transaction is valued at $381 million. Alimera Sciences is an Alpharetta, Georgia-based pharmaceutical company that develops and commercializes prescription ophthalmic retinal pharmaceuticals. Alimera has 160 employees globally and markets two products: Iluvien, which treats diabetic macular edema, and Yutiq, which treats chronic non-infectious... Read More »
Juvisé Pharmaceuticals Purchases Global Rights to PONVORY
On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple sclerosis; it is protected by several patents, the latest of which expires in 2035. Founded in 2008, Juvise Pharmaceuticals is an international pharmaceutical company based in Villeurbanne, France. Juvisé re-prioritized essential medicines in oncology (breast and prostate cancer), cardiology, gastroenterology, neuropsychiatry and rheumatology,... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
